Kinnevik Results Presentation Deck

IN APRIL WE INVESTED USD 25M INTO ENVEDA BIOSCIENCES, ADDING TO OUR EMERGING CLUSTER OF LIFE SCIENCES INVESTMENTS ■ I ■ Enveda Enveda Biosciences is a Colorado-based biotech founded in 2019 by Viswa Colluru, a PhD in cellular and molecular biology who joined our investee company Recursion as an early employee in 2016 Plant Based Drug Discovery Viswa left Recursion in 2019 to launch Enveda, and found early backing from the founders at Recursion and the team behind our partner fund Dimension In April we invested USD 25m into Enveda alongside a follow-on investment by Dimension and other insiders ■ The company focuses on mining natural products (mostly plants) for drug discovery. Nature has yielded a large share of past blockbuster drug successes such as Aspirin and Metformin, but has suffered diminishing returns due in part to our inability to understand its chemical make-up Enveda uses novel machine learning techniques such as large language models, metabolomics, and robotics to index nature's chemical space and annotate its function for new drug discovery Enveda's platform is multi-layered and IP-protected, generating a compounding, proprietary dataset, and is attracting significant interest from pharma and biotech partners Enveda fits squarely into our emerging life sciences strategy expanding our healthcare portfolio into accessing the current technology revolution in the pharma industry Enveda's Search Engine New Drugs in a Dark Chemical Space I want an @inflammasome inhibitor that is not @cytotoxic that is available in the @brain that has a @mass between 200-600. CONTINUE > Viswa Colluru, PhD CEO & Founder While at an early stage, we believe Enveda has the potential to become a truly big company over the next 5-10 years 7 KINNEVIK

View entire presentation